BRIEF-Evaxion Announces Positive Preclinical Data For Cytomegalovirus Vaccine Program EVX-V1

Reuters
12 Nov 2024

Nov 12 (Reuters) - Evaxion Biotech A/S :

* ANNOUNCES POSITIVE PRECLINICAL DATA FOR CYTOMEGALOVIRUS (CMV) VACCINE PROGRAM EVX-V1

* NEW PRECLINICAL DATA DEMONSTRATES THAT CMV ANTIGENS IDENTIFIED WITH EVAXION'S AI-IMMUNOLOGY™ PLATFORM TRIGGER TARGETED IMMUNE RESPONSES

* TO DEVELOP MULTI-COMPONENT CMV VACCINE CANDIDATE

Source text: Further company coverage:

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10